TOday’s Movers: Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Reconfirmed at BMO Capital; $21 Target Price Indicates 20.07 % Potential

August 9, 2018 - By Lisa Delgado

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Logo

Investors sentiment decreased to 1.51 in Q1 2018. Its down 0.15, from 1.66 in 2017Q4. It is negative, as 16 investors sold Halozyme Therapeutics, Inc. shares while 49 reduced holdings. 42 funds opened positions while 56 raised stakes. 119.54 million shares or 1.04% more from 118.31 million shares in 2017Q4 were reported.

Voya Investment Management Limited Com invested in 0% or 53,034 shares. Principal Finance Group Inc reported 41,951 shares stake. Btg Pactual Global Asset Mngmt Limited reported 33,365 shares. Teacher Retirement Systems Of Texas holds 28,395 shares or 0% of its portfolio. Schroder Inv Mgmt Group Incorporated has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Fisher Asset Ltd Liability Com stated it has 0.03% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Proshare Advisors Ltd Liability Company holds 0.01% or 81,407 shares. California State Teachers Retirement System holds 181,752 shares. Jpmorgan Chase & Communication invested 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Vanguard Gp Inc reported 12.02 million shares. Grp One Trading Lp owns 21,372 shares. First Advsr Ltd Partnership has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Bnp Paribas Arbitrage accumulated 0% or 35,787 shares. Alps Advsrs invested in 0.03% or 214,857 shares. Granite Inv Partners Ltd Llc, California-based fund reported 731,636 shares.

Halozyme Therapeutics (NASDAQ:HALO) Rating Reaffirmed

They currently have a $21 target on Halozyme Therapeutics (NASDAQ:HALO). The target price by BMO Capital would suggest a potential upside of 20.07 % from the company’s last price. This has been shown in a research note on Wednesday morning.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 4 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Halozyme Therapeutics has $22 highest and $19 lowest target. $20.75’s average target is 18.64% above currents $17.49 stock price. Halozyme Therapeutics had 6 analyst reports since February 21, 2018 according to SRatingsIntel. The firm earned “Underweight” rating on Friday, May 11 by Barclays Capital. BMO Capital Markets maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Thursday, February 22 with “Market Perform” rating. On Wednesday, August 8 the stock rating was maintained by BMO Capital Markets with “Market Perform”. Canaccord Genuity maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Wednesday, February 21. Canaccord Genuity has “Buy” rating and $21.0 target. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Buy” rating by Canaccord Genuity on Monday, May 14. The company was maintained on Wednesday, February 21 by JP Morgan.

The stock decreased 0.74% or $0.13 during the last trading session, reaching $17.49. About 1.19 million shares traded or 48.65% up from the average. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 46.03% since August 9, 2017 and is uptrending. It has outperformed by 33.46% the S&P500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.50 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It has a 36.67 P/E ratio. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More important recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: Streetinsider.com which released: “Halozyme Therapeutics (HALO) Reports ENHANZE Technology Utilized in Genetech’s Initiation of Phase 3 Study Of …” on July 26, 2018, also Seekingalpha.com published article titled: “Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2018 Results – Earnings Call Transcript”, Streetinsider.com published: “Halozyme Therapeutics (HALO) Announces FDA Accepted Biologics License Application For Subcutaneous …” on July 11, 2018. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) was released by: Benzinga.com and their article: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” with publication date: August 07, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.